A data-driven strategy can assess the quality of legacy drugs developed before 2011 process-validation requirements were established.
Amol Galande
Advertisement
Amol Galande is senior manager of the process development laboratory at Lupin Pharmaceuticals
Articles by Amol Galande
Advertisement
Latest Updated Articles
Assessing Legacy Drug QualityPublished: July 2nd 2021 | Updated:
Advertisement
Advertisement
